Cargando…

Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature

Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive and lethal cancer types due to the late diagnosis, high metastatic potential, and drug resistance. The development of novel therapeutic strategies is urgently needed. KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) is th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Li-Wei, Hsieh, Yao-Yu, Yang, Pei-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563462/ https://www.ncbi.nlm.nih.gov/pubmed/32947833 http://dx.doi.org/10.3390/jpm10030130

Ejemplares similares

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2021)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
por: Wu, Dandan, et al.
Publicado: (2020)

Kirsten Ras* oncogene: Significance of its discovery in human cancer research
por: Tsuchida, Nobuo, et al.
Publicado: (2016)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases
por: Song, Zizheng, et al.
Publicado: (2022)

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation
por: Wang, Yuan, et al.
Publicado: (2015)

Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis
por: Lin, Zhizun, et al.
Publicado: (2021)

Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
por: Hamilton, Gerhard, et al.
Publicado: (2023)

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report
por: Boby, Jeffrey Mathew, et al.
Publicado: (2022)

Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway
por: Ruan, Hao, et al.
Publicado: (2021)

Solitary acrometastasis of the phalanx as initial presentation of an oligometastatic Kirsten rat sarcoma viral oncogene homolog-mutated lung adenocarcinoma: a case report
por: Pușcașu, Alexandra-Ioana, et al.
Publicado: (2023)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription
por: Cogoi, Susanna, et al.
Publicado: (2018)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
por: Li, Jia-Xin, et al.
Publicado: (2022)

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report
por: Rossing, Henrik H, et al.
Publicado: (2013)

Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative Stress
por: Cinque, Giorgio, et al.
Publicado: (2020)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations
por: Zhang, Hong, et al.
Publicado: (2015)

Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
por: Lee, Jae-Hoon, et al.
Publicado: (2016)

Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis
por: Sakamoto, K, et al.
Publicado: (2005)

Pseudocirrhosis in Chronic Budd Chiari Syndrome With Janus Tyrosine Kinase 2 (JAK2) Mutation
por: Lakshmanan, Seetha, et al.
Publicado: (2020)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
por: Mesa, Ruben A., et al.
Publicado: (2021)

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells
Publicado: (1995)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6
por: Kidger, Andrew M., et al.
Publicado: (2022)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
por: Chary Nimmagadda, Subbaiah, et al.
Publicado: (2023)

Ab Initio Modeling and Experimental Assessment of Janus Kinase 2 (JAK2) Kinase-Pseudokinase Complex Structure
por: Wan, Xiaobo, et al.
Publicado: (2013)

Association between Polymorphism in the Janus Kinase 2 (JAK2) Gene and Selected Performance Traits in Cattle and Sheep
por: Oster, Nicola, et al.
Publicado: (2023)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair
por: Yang, Linlin, et al.
Publicado: (2021)

Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated None—Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure
por: Barbie, David A., et al.
Publicado: (2018)

JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells
por: Oh, Yunmoon, et al.
Publicado: (2022)

Targeting the JAK2/STAT3 Pathway—Can We Compare It to the Two Faces of the God Janus?
por: Jaśkiewicz, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6165onrklo0m2dt8asef82a4ar